ES2293748T3 - Moleculas de fijacion poliespecificas y usos de las mismas. - Google Patents

Moleculas de fijacion poliespecificas y usos de las mismas. Download PDF

Info

Publication number
ES2293748T3
ES2293748T3 ES99970601T ES99970601T ES2293748T3 ES 2293748 T3 ES2293748 T3 ES 2293748T3 ES 99970601 T ES99970601 T ES 99970601T ES 99970601 T ES99970601 T ES 99970601T ES 2293748 T3 ES2293748 T3 ES 2293748T3
Authority
ES
Spain
Prior art keywords
chain
tcr
protein
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99970601T
Other languages
English (en)
Spanish (es)
Inventor
Jon A. Weidanz
Kimberlyn Card
Linda A. Sherman
Norman R. Klinman
Hing C. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altor Bioscience LLC
Original Assignee
Altor Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience LLC filed Critical Altor Bioscience LLC
Application granted granted Critical
Publication of ES2293748T3 publication Critical patent/ES2293748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES99970601T 1998-10-21 1999-10-21 Moleculas de fijacion poliespecificas y usos de las mismas. Expired - Lifetime ES2293748T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10516498P 1998-10-21 1998-10-21
US105164P 1998-10-21

Publications (1)

Publication Number Publication Date
ES2293748T3 true ES2293748T3 (es) 2008-03-16

Family

ID=22304401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99970601T Expired - Lifetime ES2293748T3 (es) 1998-10-21 1999-10-21 Moleculas de fijacion poliespecificas y usos de las mismas.

Country Status (9)

Country Link
US (3) US6534633B1 (cg-RX-API-DMAC7.html)
EP (1) EP1124568B1 (cg-RX-API-DMAC7.html)
JP (1) JP4467188B2 (cg-RX-API-DMAC7.html)
AT (1) ATE370967T1 (cg-RX-API-DMAC7.html)
AU (1) AU1218000A (cg-RX-API-DMAC7.html)
DE (1) DE69936927T2 (cg-RX-API-DMAC7.html)
DK (1) DK1124568T3 (cg-RX-API-DMAC7.html)
ES (1) ES2293748T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000023087A1 (cg-RX-API-DMAC7.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7524601A (en) * 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
ES2307770T3 (es) 2001-06-05 2008-12-01 Altor Bioscience Corporation Moleculas receptoras de las celulas t fijadoras de p53 y usos de las mismas.
WO2004050705A2 (en) * 2002-12-03 2004-06-17 Avidex Ltd. Complexes of receptors
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
AU2004289316B2 (en) 2003-11-10 2011-03-31 Altor Bioscience Corporation Soluble TCR molecules and methods of use
US7964380B2 (en) * 2005-01-21 2011-06-21 Argylia Technologies Nanoparticles for manipulation of biopolymers and methods of thereof
GB0507046D0 (en) * 2005-04-06 2005-05-11 Celltech R&D Ltd Primers
WO2007048849A1 (en) * 2005-10-28 2007-05-03 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
EP1982176A1 (en) * 2006-01-30 2008-10-22 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
CA2656222C (en) 2006-06-26 2018-07-17 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
EP2038074B1 (en) * 2006-06-29 2014-06-11 Xiaolian Gao Make and use of surface molecules of varied densities
US8569464B2 (en) * 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) * 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US20110070191A1 (en) * 2008-03-19 2011-03-24 Wong Hing C T cell receptor fusions and conjugates and methods of use there of
WO2009151514A1 (en) * 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2303230A2 (en) * 2008-07-10 2011-04-06 ESBATech, an Alcon Biomedical Research Unit LLC Methods and compositions for enhanced delivery of macromolecules
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US20100190963A1 (en) * 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
ES2754210T3 (es) 2010-05-17 2020-04-16 Emd Millipore Corp Polímeros sensibles a estímulos para la purificación de biomoléculas
JP2013533738A (ja) * 2010-06-08 2013-08-29 イー・エム・デイー・ミリポア・コーポレイシヨン 生体分子の精製に使用されるポリマーの残存量を検出する方法
EP3388451A1 (en) 2011-09-29 2018-10-17 Apo-T B.V. Multi specific binding molecules targeting aberrant cells
AU2012318609B2 (en) 2011-10-05 2018-02-08 The Rockefeller University Dimeric bacteriophage lysins
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2014352826B2 (en) 2013-11-22 2019-08-01 The Board Of Trustees Of The University Of Illinois Engineered high-affinity human T cell receptors
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
FI3464380T3 (fi) 2016-06-02 2025-01-31 Immunocore Ltd Gp100-spesifisen tcr-anti-cd3 scfv-fuusioproteiinin annosteluohjelma
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
KR20250089564A (ko) 2017-02-08 2025-06-18 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2018166589A1 (en) * 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
CN111655280B (zh) 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
CN112055595B (zh) 2018-01-22 2024-12-17 恩多塞特公司 Car t细胞的使用方法
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CA3217739A1 (en) 2021-05-05 2022-11-10 Sebastian Bunk Bma031 antigen binding polypeptides
KR20250133399A (ko) * 2023-01-05 2025-09-05 앤젤레스 테라퓨틱스, 인코포레이티드 유전자 전달 및 합성 및 면역 수용체의 활성을 제어하기 위한 방법 및 조성물
GB202320012D0 (en) * 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2098368T3 (es) 1990-08-09 1997-05-01 Nat Jewish Ct Immun & Respirat Produccion de anticuerpos monoclonales contra un elemento vbeta humano de los receptores de las celulas t, utilizando vectores de adn recombinante.
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
AU729406B2 (en) * 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
EP1019439B1 (en) * 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins

Also Published As

Publication number Publication date
DE69936927D1 (de) 2007-10-04
DK1124568T3 (da) 2008-01-02
US6534633B1 (en) 2003-03-18
EP1124568A1 (en) 2001-08-22
US20030171552A1 (en) 2003-09-11
EP1124568A4 (en) 2003-08-27
JP2004537952A (ja) 2004-12-24
ATE370967T1 (de) 2007-09-15
EP1124568B1 (en) 2007-08-22
WO2000023087A1 (en) 2000-04-27
US20120230995A1 (en) 2012-09-13
DE69936927T2 (de) 2008-05-15
US8105830B2 (en) 2012-01-31
JP4467188B2 (ja) 2010-05-26
AU1218000A (en) 2000-05-08

Similar Documents

Publication Publication Date Title
ES2293748T3 (es) Moleculas de fijacion poliespecificas y usos de las mismas.
KR102710963B1 (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
CN105377886B (zh) 识别mage-a1的高亲和力结合分子
KR100712256B1 (ko) 가용성 단일쇄 ｔ-세포 수용체 단백질
EP2322228B1 (en) T cell receptor fusion proteins and conjugates and methods of use thereof
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
ES2315016T3 (es) Moleculas llamadas b7l-1.
Yang et al. Differential expression of CD8 epitopes amongst porcine CD8‐positive functional lymphocyte subsets
TR201909647T4 (tr) Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car).
US12492252B2 (en) Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
Lunde et al. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies
CN118678964A (zh) Ig样融合蛋白及其用途
JP2023525778A (ja) 抗ｂｃｍａ抗体およびキメラ抗原受容体
CA2120036A1 (en) Method of producing antibodies to a restricted population of t lymphocytes, antibodies produced therefrom and methods of use thereof
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
AU4909199A (en) Immunological reagent specifically interacting with the extracellular domain of the human zeta chain
CN116194574A (zh) 嵌合抗原受体细胞
CA3209169A1 (en) Preparation of siglec-15 binding protein and use thereof
CN118994391A (zh) 特异性结合cd38的抗体及其制法和应用